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The contemporary physician and
his patient are riding the crest of
the most dramatic expansion of
medical capability in history. But
the rapid proliferation of medical
knowledge has not been entirely
benign. Although our reverses have
been minor in contrast to our advances, negative effects cannot be
ignored. My discussion involves
one aspect of this problem-the
emergence of what I have called
"Diseases of Medical Progress"
(Moser, 1964) .
Pertinent to the evolution of
medical capability has been the
improvement in quantity and quality of drugs. In the early days new
drugs came in a trickle, and there
was time for the physician to become familiar with their virtues
and idiosyncrasies. Soon the trickle
became a stream, and there was
less time for study and reflection.
The stream has now become a torrent; it is impossible for the physician to keep pace. His little black
bag runneth over.
It has been said that druginduced adverse effects are the
price we have to pay for more
effective medicaments (Zbinden,
1964). There can be no quarrel
with this statement; it is the high
price we are haggling about. The
thalidomide disaster indicated how
expensive it can be.
The deluge of new drugs has
produced widespread discontent
with empiricism in therapeutics.
The modern practitioner demands
drugs with proper credentials. This
has precipitated a virtual renaissance in drug investigation, and
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thus we have come to learn more
of the wonders and hazards of contemporary therapeutic agents.
The demands of the clinician to
know more about drugs are being
met by increasing capability in the
laboratory. New insight and appreciation of the complexities of
drug effects have come from several diverse avenues of investigation. The wedding of percutaneous
biopsy and electron microscopy
has resulted in dramatic revelations; the mysteries of intracellular morphology and physiology in
the living organism have begun to
yield. Often, we are able to observe the specific site of drug action within the cell.
In other areas techniques continue to be perfected for assay of
blood and tissue levels of drugs,
intermediate products and enzymes.
The problems of adverse drug effects are many. Reduced to simplest elements, when Drug "A" is
introduced into the body, ultimately it or its intermediate products will be carried in blood and
body fluids to all cells of the organism. The effects of Drug "A"
become clinically perceptible only
when the function of certain organs
is modified, either beneficially or
detrimentally, to the point of producing perceptible changes, and it
is by these phenomena that we
learn to characterize the nature of
Drug "A." As we focus attention
upon the response of a specific
organ (or organs) to th is drug, we
are inclined to forget that Drug
"A" is also in contact with other
tissues of the organism. Effects in
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these areas are not immediately detectible, but may become manifest
clinically at a later date. Such longrange effects may never be correlated with the antecedent administration of Drug "A."
Only painstaking retrospective
analysis of many cases will uncover
a suspected denominator. Then we
must follow with a meticulously
controlled prospective study which
will involve provocative testing in
acceptable laboratory animals before we can prove that indeed it
was Drug "A" that caused the
chronic disease. The problems of
extrapolating this data to humans
are evident. This is a shadow world
of pathophysiology where relation
of cause to effect is at best difficult
to assess. I need only cite the still
raging controversy over phenacetin and renal disease to demonstrate the difficulty. There are other
problems.
What is known of the role
played by drugs in predisposing the
organism to attack by micro-organisms or degenerative disease? An
example is the effect of long-term
corticosteroids in predisposing the
leukemia or lymphoma patient to
systemic fungus infections.
We are hearing more about the
so-called "opportunistic organisms"
- perhaps a semantically poor euphemism. But it is appropriate to
our thesis to mention Candida albicans (Seelig, 1966). This is a
saprophyte of limited pathogenicity
under normal circumstances, but
may emerge as a systemic infection
and seed into many organs during
or following broad spectrum antibiotic administration, with or without concomitant corticosteroid or
immunosuppressive therapy. This
phenomenon has been related to
suppression of susceptible enteric
flora with disruption of the normal
ecologic balance permitting the unsuppressed saprophytes to proliferate and escape their enteric confines.
The devastating influence of prolonged corticosteroid therapy upon
the elderly patient immobilized by
cardiovascular disease or arthritis,
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in whom accelerated demineralization occurs through corticosteroid
anti-anabolic effect, is an example
of exaggeration of degenerative disease caused by a drug. We start
with one disease and our treatment
for it produces another disease.
Let us modify the question again.
What is known of the effects of
drugs upon a previously diseased
organ, with limited capability to
metabolize or detoxify or otherwise
cope with a drug given to treat
another illness? I have mentioned
the phenacetin controversy. The
discussion here revolves around the
status of analgesic compounds in
the provocation of interstitial pye.lonephritis in a normal kidney. But
what effect do phenacetin, aspirin,
or the combination have upon a
sick kidney, already poorly disposed to resist assault from either
micro-organism or nephrotoxic
drug?
Consider the patient with subclinical hepatic disease, e.g., a mild
cirrhosis, who is given chlorpromazine or phenylbutazone, drugs
known to be occasionally toxic to
the liver. One could cite multiple
examples wherein an organ with
marginal function may be further
insulted by a drug administered,
most innocently and with proper
indication, to treat another ailing
system.
Pharmacogenetics and Enzyme
Induction

Perhaps the most fascinating
corollary to these observations is
the identification of a relationship
between enzyme systems and drug
effects. Vogel (1959) introduced
the term "pharmacogenetics" into
clinical medicine. This was defined
as "the study of genetically determined variations that are revealed solely by the effects of
drugs." The genetic variation results in the absence or insufficiency
of certain enzyme systems. This
mechanism has already been cited
as one major explanation of the extraordinary human variability in
response to conventional doses of

conventional drugs (Evans, 1963).
The historical and classical example of a pharmacogenetic disease is the hemolytic anemia suffered by some members of certain
ethnic groups, specifically, Mediterranean basin dwellers and Negroes
(Berry, 1965; Beutler et al., 1955).
Brisk hemolysis may follow exposure to many common therapeutic agents (among these are the
4-aminoquinolines, certain sulfonamides, acetylsalicylic acid, the nit r of ur ant o ins, sulfones, paraamino-salycylic acid, phenacetin
acetanilid, probanthine and the
water soluble analogues of vitamin
K). Even the Fava bean apparently
provokes hemolytic anemia on the
same basis.
The cause is a genetically transmitted defect that results in deficiency of the intra-erythrocytic
enzyme, glucose-6-phosphate dehydrogenase. Such patients are normal clinically; they have no morphologic or physiologic abnormality
of their red cells, until one of the
provocative drugs is given. Then
brisk hemolysis occurs. Deficiency
of glucose-6-PD has been cited as
one cause of neonatal jaundice. It
is somewhat of a problem in the
chloroquine primaquine anti-malarial prophylaxis program in Southeast Asia (personal communication, Col. Marshal McCabe).
Other red cell enzyme deficiencies of greater subtlety have begun
to emerge; these include aldolase,
catalase, glutathione, glutathione
reductase, pyruvate kinase, triose
phosphatase and isomerases.
In addition, kernicterus of the
newborn is related to immaturity
of the neonatal liver. This organ is
deficient in glucoronosyl transferase and, therefore, unable to conjugate bilirubin. Administration of
sulfisoxazole (Gantrisin) or vitamin K analogues exaggerates this
reaction. Novobiocin may provoke
jaundice in the newborn and rarely
in adults by direct inhibition of
glucoronosyl transferase (Moser,
1967, in press).
Do these adults have a marginal
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deficiency of this enzyme which
becomes evident only when they
are challenged with novobiocin? Is
it congenital, or is it acquired as
the result of a preceding episode of
hepatic disease?
There are other equally fascinating pharmacogenetic diseases.
Hemoglobin Zurich (Frick, Hitzig,
and Betke, 1962) is an example. If
a certain Swiss family had not been
given sulfonamide drugs, it is quite
likely that this abnormal hemoglobin disease would have continued
to escape detection. A frank hemolytic anemia developed after administration of sulfadimethoxine and
sulfamethoxypyridizine (Kynex) to
family members. A new hemoglobin with electrophoretic mobility
between A and S was identified;
fingerprints of peptic digests revealed three unusual peptides.
Time permits only a brief glance
at other equally fascinating pharmacogenetic disorders.
( 1) Hemoglobin H disease : patients with this illness have hemoglobin which is a tetramer of four
beta chains. Their erythrocytes appear normal until they are given
sulfisoxazole ; then a brisk hemolytic anemia may develop.
(2) Patients may be divided into
phenotypes on the basis of their
ability in inactive isoniazid (Porter, 1964; Editorial, S. African
Med. J., 1964). There is reason to
suspect that isoniazid polyneuropathy is more common in "slow inactivators" than "rapid inactivators." Fortunately there 1s no
difference in therapeutic responsiveness to isoniazid, and the development of resistance by the
tubercle bacillus to isoniazid is
similar in the two phenotypes.
(3) About 1 % to 2% of patients have a genetically determined
deficiency of pseudocholinesterase
(Hodgkin et al., 1965) ; This may
be qualitative or quantitative. The
malady will remain asymptomatic
and undetected unless the patient
is challenged with suxamethonium.
Then the response is dramatic; a
2 to 3 min period of apnea will

ensue. Pseudocholinesterase is required to metabolize suxamethonium.
( 4) It is suspected that increased susceptibility to dyskinesias
subsequent to administration of
phenothiazines such as chlorpromazine, may have a genetic basis.
And in view of the multitude
of known enzyme systems, as well
as those suspected but not as yet
identified, one could predict that
many reactions now classified as
idiosyncratic or hypersensitive will
soon be gathered into the fold of
pharmacogenetic disorders or acquired enzyme insufficiencies.
A related phenomenon is druginduced inhibition of the metabolic
breakdown or release of albumin
binding with escape of free drug.
This is epitomized by the potentiation of coumarin drugs by several rather common agents, such
as phenyramidol (Carter, 1965) ,
acetyl salicylic acid, tetracycline,
streptomycin, D-thyroxi ne, androsteneolone, phenylbutazone (Eisen,
1964) and oxyphenbutazone (Fox,
1964).
Now there is a new dimension,
quite antithetical to the concept of
enzyme deficiencies unmasked or
inhibition of metabolic breakdown
caused by drugs. This is the· phenomenon of "enzyme induction,"
in which the administration of one
drug accelerates the metabolic
breakdown of another. (Burns, et
al., 1965; Conney and Burns, 1963 ;
Fouts, 1963) . Clinical suspicion
was aroused when it was discovered that some patients receivil)g
coumarin drugs required increased
doses to maintain therapeutic anticoagulant levels while taking barbiturates.

Residual Drug Effects
Residual drug effects re.main another enigmatic area. For example,
reserpine continues to exert its
influence jn certain patients for
several weeks after it has been discontinued. It may cause unpredictable responses to general anesthe-

sia. Reserpine may obscure the
phentolamine (Regitine) test for
pheochromocytoma for several
weeks after it has been stopped.
The persisting and even progressive
retinal damage induced by residual chloroquine has been the subject of much commentary.
Elevated levels of protein bound
iodine were found in the sera of
women who had received iophenoxic acid (Teridax, a cholecystographic medium) six to seven years
previously. Babies born several
years after their mothers had ingested iophenoxic acid had extremely high levels of protein
bound iodine (Goss and Dickhaus,
1965). These agents may lie dormant in fat depots for many years,
apparently innocuous, but in curious contradiction to the usual tendency of an organism to rid itself of
foreign substances. What other
drugs are "stored" for prolonged
periods? Do they exert adverse effects? Questions come easily; answers do not.
An equally fascinating new aspect of drug mechanisms is revealed
in the recently recognized phenomenon of transferable drug resistance. This was first observed in
Japan in 1959 during studies on
Shigella which proved resistant to
several anti-microbial agents. It is
now recognized that Shil!ella and
Salmonella are capable of genetic
transm1ss10n of drug resistance
(Smith, 1966). It has been suggested that the widespread use of
antibacterial drugs in agricultural
feeds has contributed to this problem . To my knowledge genetically
transferred resistance factors have
been identified only in gram-nel!ative micro-organisms and acid-fast
bacilli.
Now that we have seen something of the broad introductory
area of drug-induced diseases, a
logical question might be: What
will be the ultimate effect of these
new therapeutic endeavors? The answer must lie somewhere in the interface between philosophy and
physiology.
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The evolution of man is a continuing source of wonderment to
students of physiology. Through
the centuries of painful metamorphosis, each challenge thrown at
man by his environment was met
by a gradual genetic modulation
that enabled him to survive. The
species has arrived at the current
state of advanced physiologic capability-admirably adapted to its
environment. We can dig diamonds
at 9,000 feet in 123° heat and
100% humidity; we can spend a
lifetime mining tin at a 14,900-foot
elevation, we can hike across the
pole, and we can float weightlessin-space for 14 days.
But in the past few decades we
have devised techniques unprecedented in the previous experience
of the species to challenge the
adaptability of the organism. We
have designed molecules unique to
human physiology and have intruded them into blood and tissue
by techniques that are also unique
in physiologic experience. Intravenous, intramuscular and subcutaneous injections, positive pressure inhalation, rectal administration, and
agents that facilitate passage
through intact skin all are unfamiliar modes of gaining access to the
body. Add, for example, radiation
by x-ray, beta ray, gamma ray and
neutrons, plus oxygen under greatly
increased barometric pressure, and
one begins to appreciate the magnitude and genius of man's conspiracy to by-pass the conventional
avenues for introducing new environmental factors to the physiology
of man.
In the past we only had to cope
with nature and environment. And
they were confined to the gastrointestinal tract, lungs and occasionally the abraided skin to admit
alien materials to the core of man.
The implications of these ingenious tactics of assault, these strange
man-made chemicals and emanations upon the beleaguered human
mechanism are fascinating to contemplate. One could speculate that
this incredibly resilient physiologic
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machine of ours is sufficiently advanced in design to be able to cope
with all transgressors. We have
evolved defenses at all levels from
the simplest reflex to the most complex immune reactions to meet the
daily challenges of environment.
And we have done very well in the
matter of self preservation.
Yet it is quite evident that some
of these unprecedented therapeutic
intrusions will overtax the ability
of the body to accommodate, and it
will react with displeasure, if not
violent rejection. Of course this is
the heart of our thesis, drug-induced diseases.
Every new drug must be evaluated for efficacy and toxicity, and
this is not an easy task. Only passage of time and acquisition of experience will determine the ultimate
verdict. Firm pronouncements
based on animal experimentation or
fragmentary early clinical trials are
premature and meaningless. Often
it takes years before the full spectrum of efficacy or toxicity of a
drug becomes evident. This poses
an almost insoluble conundrum. If
we are timid and withhold the drug,
how will we ever gain the necessary
clinical experience? If the agent is
effective and safe, it would seem
unfair to withhold it. But if the
drug is ineffective or toxic, it would
seem equally unfair to use it on patients. All that one can propose is
prudence, caution, and reservation
of final judgment until objective
studies are completed.
In an effort to dramatize the
problem of drug toxicity, I have
selected one group of drugs, the
tetracyclines, to serve as a prototype to illustrate the continuing
challenge that faces the medical
profession in arriving at a comprehensive appreciation of the spectrum of toxic effects of drugs. One
might select almost any popular
drug to do the same thing. This
could properly be called the evolution of the toxic profile of a drug.
Tetracyclines are valuable therapeutic allies. They qualify as antibiotics of choice in a host of in-
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fectious diseases. So let it be
established at the outset, there is no
denying the efficacy of tetracyclines
in clinical medicine.
Included in this group of drugs
are chlortetracycline (Aureomycin)
oxytetracycline (Terramycin), tetracycline, tetracycline phosphate
and rolitetracycline.
Chlortetracycline was introduced
in 1947. Despite the wearisome
flurry of superlatives that attends
the introduction of every major
new drug, chlortetracycline was
found to be remarkably effective.
By 1949, a reflective review of the
literature on this drug stated "it
is an important landmark in the
field of antibiotics. Its extremely
low toxicity and wide range of activity and absorbability from the
gastrointestinal tract combine to
make it a powerful therapeutic
weapon" (Rose and Kneeland,
1949). A prodigious literature extolling its virtues soon accumulated.
Early adverse effects were minor.
They could almost be characterized
as annoyances, and they were confined to the gastrointestinal tract.
Loss of appetite, nausea, vomiting,
flatulence, dyspepsia and diarrhea
occurred in about 10 % of patients
receiving significant doses (Pflug,
1963; Schindel, 1965; Bevelander,
1963). For several years the profession was quietly congratulating
itself on having found a new variety
of wonder drug with broad application and low toxicity. Even the
appellation "broad spectrum antibiotic" had a solid ring, adding a dimension of comprehensive coverage and confidence.
In the early 1950's slight rumblings could be heard in this therapeutic paradise. Other adverse effects related to gastrointestinal tract,
more severe than the early ones,
began to creep into clinical cognizance.
Antibiotics, especially the tetracyclines, can disrupt the normal
ecologic balance of the colon. Destruction of friendly commensals
facilitates overgrowth of organisms

resistant to the antibiotic. And, of
course, if any of these hostile bacteria escape their enteric confines
and gain access to blood or urinary
tract, they can cause significant mischief.
This alteration of bacterial flora
has been associated with stomatitis,
glossitis, pharyngitis, and black
hairy tongue, a cosmetically grotesque, but pathologically benign
condition. Also xerostomia, hoarseness, and vulvo-vaginitis were related to tetracycline treatment. In
most of these situations, disruption
of bacterial balance permitted the
fungus Monilia Albicans to flourish
in these unseemly sites (Pflug,
1963 ; Bonniot, 1964; Caruso, 1961;
Clendenning, 1965).
A corollary phenomenon was the
rare occurrence of bleeding in elderly patients with cirrhosis of the
liver. It was postulated that the
damaged liver was less efficient in
producing its coagulation factors.
Added to this was the belief that
Vitamin K synthesis in the small
bowel was inhibited by the alteration of flora incident to tetracycline
administration. But now this mechanism is strongly disputed. A final
step in this hypothetical pathogenesis was that the sick liver, already
struggling to produce its coagulation factors, had its supply of Vitamin K cut off. Therefore, no Vitamin K, no coagulation factor-and
we have bleeding. Unfortunately,
there is little evidence to support
this concept.
It was in 1958 that from the
British Isles, Germany, and Scandanavia came word that an old scourge
was revisiting us with a vengeance.
This was the granddaddy of all
gastrointestinal syndromes that tetracyclines and other antibiotics had
caused: staphylococcal pseudomembranous entercolitis (Bonniot,
1964; Caruso, 1961; Clendenning,
1965; Altemeier, Hummel, and
Hill, 1963; Nemeth, Feher, and
Szinay, 1963; Pockrandt, 1964; Sivertssen and Juel, 1958; Wegmann
and Bucher, 1964). Once the
friendly bacteria had been deci-

mated by the antibiotic, the Staphylococcus, previously suppressed by
normal bacterial inhabitants, had
gained ascendency and invaded the
colon wall. This resulted in destruction of the superficial cellular
layers, with necrosis and sloughing.
The result was a denuded colon
wall which wept vast amounts of
fluid, and death was not an infrequent consequence.
This dread complication had
been known before antibiotics, but
there was a distinct impression that
the incidence had risen significantly
with the use of antibiotics, including the tetracyclines. It was a tragic
paradox that in some instances the
antibiotics had been given in a sincere but naive effort to prevent the
development of a bacterial infection.
In the early 1960's, rare sporadic
cases were recorded describing a
variety of hypersensitivity reactions.
These included sudden cardiovascular collapse due to anaphylaxis,
(Bedford, 1951 ; Editorial, J.A.M.
A., 1965; Fellner and Baer, 1965).
Others included ecchymoses (Schoenfeld, 1964) , hemolytic anemia
(Takahashi, 1963), and dermatologic reactions (Schindel, 1965).
A related and even more curious problem was the reactivation
of systematic lupus erythematosus
(Domz et al., 1959). Some observers even reported the precipitation
of this disease de novo, following
the administration of tetracyclines
(Sulkowski and Haserick, 1964) .
This must be an unusual occurrence, since I have seen no subsequent reports.
In early 1963, a paper appeared
which described a new entity related to tetracyclines. It bore superficial resemblance to diabetes mellitus, since there was an excess of
glucose in the urine and even albumin. But closer scrutiny revealed
that amino-acids also were being
excreted. Thus it conformed to the
pattern that had only been ohserved
previously in patients with the Fanconi syndrome (Cleveland et al.,
1965; Castell and Sparks, 1965;
95

IATROGENIC DISORDERS

Editorial, Medicina, 1965; Frimpter, Timpanelli; and Eisenmenger,
1963; Fulop and Drapkin, 1965;
Gross, 1963; Rice, Anderson, and
Clark, 1964).
It was an intriguing situation,
especially when the cases were collated and it was discovered that all
victims had ingested out-dated tetracycline. The mysterious malady
regressed about one month after
the drug had been withdrawn.
Warnings went out to physicians
and pharmacists advising them to
prescribe precise amounts of tetracycline and to admonish thrifty patients to clean out the medicine
chest. The American tradition of
family sharing of unused antibiotics
was publicly denounced.
A paucity of subsequent reports
seemed to indicate that the pharmaceutical industry had modified the
procedure by deleting citrate to obviate the problem of tetracycline
degradation. However, two recent
cases were reported in which potassium depletion was a remarkable
feature of a Fanconi Syndrome,
again induced by out-dated tetracycline.
This incident called to mind
some earlier work linking tetracycline toxicity and renal disease (Editorial, Ann. Int. Med., 1963; Mavromatis, 1965; Pulliam and O'Leary,
1964; Robins, 1963; Shils, 1963;
Solomon, Galloway, and Patterson,
1965; Wegienka and Weller, 1964;
Zimmerman and Werther, 1964).
These antibiotics tend to interfere
with protein synthesis. In patients
with poor kidney function, tetracyclines may exaggerate elevation
of blood urea nitrogen. Rarely, an
excessive sodium diuresis may
cause hyponatremia. As the kidney
disease becomes more severe and
function declines, the tetracyclineinduced problems are compounded
proportionately. Severe retention of
protein breakdown products, urea
and phosphate, resu1t in a metabolic
acidosis, and this· could cause loss
of weight, uremic symptoms, including anorexia, nausea and vomiting. Tetracycline adminstration to
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the unfortunate patient with severe
renal disease may result in exacerbation of clinical uremia; gastric
ulceration and bleeding has been
reported.
In 1963 a new dimension was
added to the tetracycline story. It
was discovered that these drugs had
a strange affinity for teeth, bones
and tumors (Benson, 1964; Cuttita,
1965; Editorial, J. Am. Dental
Assoc., 1964; Editorial, Lancet,
1965; Editorial, Nutrition R ev.,
1964; Frankel and Hawes, 1964;
Hilton, 1962; Kutscher, et al.,
1963; Kvaal, 1965; Madison, 1963;
Stewart, 1964; Swallow, 1964; Taguchi, 1963; Vickers, 1964; Wallman and Hilton, 1962; Weyman,
1965; Witkop and Wolf, 1963) . A
group of 50 young children were
receiving long-term chlortetracycline or oxytetracycline for the control of pulmonary infection associated with cystic fibrosis. Staining
of the teeth occurred in 80%.
Those given tetracyclines in early
infancy exhibited the most ·severe
discolorations.
Apparently tetracycline has an
affinity for the active growth sites
of bones and teeth; it migrates to
these areas soon after it is given,
and there it remains. A definite inhibition of normal calcification occurs at these sites of tetracycline
deposition.
In teeth this amounts to delayed
growth and intrinsic staining of
dental enamel; this may be the
commonest cause of deciduous
enamel discoloration in infants.
Perhaps equally distressing is the
capability of tetracyclines to migrate through the maternal placenta
to be deposited in the skeleton of
the fetus (Tubaro, 1964). In premature infants this could cause inhibition of bone growth. On a happier note, it must be noted that this
effect is reversible if the course of
tetracyclines given to the mother is
brief.
Other authors have suggested
that tetracyclines administered to
women in early pregnancy could
result in congenital abnormalities·in

their off-spring (Barkalaia, 1964;
Manning, 1964; Cobian, Bevelander, and Tiamsic, 1963) . The data
here was entirely inferential. This
did call to mind a paper published
in 1963, which described a strange
phenomenon in which tetracyclines
administered to six infants caused
a rise in cerebro-spinal fluid pressure with bulging of the fontanelle.
This process regressed promptly
upon withdrawal of the drug (Opfer, 1963). This is most assuredly
a rare adverse effect. I have seen
no subsequent reports of this phenomenon.
In another direction it has been
observed that some individuals who
are taking tetracyclines develop increased sensitivity to sunlight (deVeber, 1962; Kingsley, 1963 ; Saslow, 1961; Soga!, 1963; Storck,
1965; Tromovich and Jacobs,
1963). This apparently is more severe with demethylchlortetracycline,
but has occurred with others of the
group. This may take a rather
severe form on rare occasions with
actual epidermolysis.
Later a report described a young
lady who became myopic while
taking tetracycline; it disappeared
when she stopped the drug (Capperucci, 1964; Edwards, 1963).
Later a few others made similar
observations.
In 1964, Dr. Searcy and coworkers reported that tetracycline
when given intravenously interfered
with coagulation of blood (Searcy,
Simms, and Foremar, 1964; Searcy
et al., 1965). This was considered
to be a direct effect against specific
clotting factors. These patients did
not have liver disease and there
was no apparent disturbance of
Vitamin K production.
In late 1963, the New England
Journal of M edicine carried an article that described the deadly misfortunes of six young pregnant
women who developed kidney infections. They were given tetracycline intravenously in larger than
average doses by the intravenous
route. All died within 5 to 13 days
after the start of tetracycline treat-
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ment. Examination at post mortem
revealed identical changes in their
livers (Schultz et al., 1963) . Several more cases were reported subsequently (Brewer, 1965; Cairella,
Trasatti, and Becchi, 1964; Editorial, Brit. Med. J., 1964; Finn and
Horwitz, 1965; Horwitz and Marymont, 1964; Kunelis, Peters, and
Edmondson, 1965; Norman,
Schultz, and Hoke, 1964; Orentreich and Berger, 1965; Popper et al.,
1965: Wruble et al., 1965 ; Wruble
and Cummins, 1965).
This episode was climaxed by a
formal statement by the American
Medical Association, Council on
Drugs. "Tetracycline given intravenously should be prescribed with
caution in women in the last trimester of pregnancy. When administered, its concentration in serum
should be controlled and liver function tests should be made at frequent intervals. Finally, it is important that physicians refrain from
prescribing other potentially hepatotoxic drugs concomitantly" (Dowling and Lepper, 1964) .
This appeared on April 20, 1964.
It was a conservative statement at
the time. Today we have other
drugs with the same area of effectiveness as tetracyclines, but with
no known toxic effect upon the
liver.
And all of this is not over. Just
a few months ago an article appeared describing thrombocytopenia
related. to tetracyclines (FDA Reports, 1966). And this was almost
20 years after the first clinical experience with this group of drugs.
Again I wish to emphasize that
tetracyclines are valuable antibiotics. I prescribe them; all of us do,
but they are not entirely benign
(Moser, 1966). And it has taken
almost 20 years to appreciate this.
One may ask, how can it be that
it takes so lon{?? The answer is
not easy. I can cite my own experience .with another drug. Soon after
it appeared on the market, I prescribed Serpasil for a patient. Soon
she complained of paresthesias and
tremors.

I searched the literature; there
was nothing. I considered this a
neurotic manifestation, patted my
patient on the head, and persisted
in my naivete and ignorance. Finally symptoms became more severe; I stopped the drug; symptoms
regressed. I started the drug again;
symptoms recurred. At least I was
convinced. The patient (who happened to be my wife) was also convinced that I was an idiot. And
one week later the first article appeared on Serpasil-induced tremors.
This is not an uncommon experience, and that is why it often takes
20 years.
Conclusion

"Diseases of Medical Progress"
will be with us forevermore. They
cannot be swept under the rug,
either by clinician or drug producer. My own naivete in the world
of commerical enterprise is revealed
by my admission that I think a fine
new drug will become known to the
profession on the basis of its merit.
I am embarrassed when this noble
community is demeaned by merchandizing techniques, however
subtle or artful, better suited to less
vital products, such as soap or soda
pop. The fact that over . $750 million is spent each year for drug advertising is a staggering testimonial
to the enormity of this effort. This
is almost three times more money
than is required to run all of the
medical schools in this country for
one year. I do not feel that drugs
should be propagandized to the
medical profession. The pressure of
commercial competition is not conducive to objectivity in the presentations' of drug detail men or in
published advertisements. ·I · feel
these factors add to the confusion
in the already .difficult prob lems of
evaluating the efficacy or adverse
effects of new drugs.
The requirement for a'n impartial
agency that can provide current,
reliable and objective data ·about
the characteristics of riew drugs,
and alert the physieiari to their
0

toxic hazards is abundantly evident. This requirement has been
met by the American Medical Association Council on Drugs, which
created a national "Registry of Adverse Reactions. " A comparatively
new facility, it was the natural successor to the "Registry of DrugInduced Blood Dyscrasias," a most
successful pioneer study guided and
nurtured by Dr. Maxwell M. Wintrobe and Dr. Charles Huguley.
The new, broader registry makes it
possible for any physician to contribute his personal experience with
adverse drug effects to a central
pool. This information is recorded
on a form designed for automatic
data processing. The data are extracted and recorded in the memory
banks of a computer system.
Volunteer teams of nationally
recognized specialists study all information submitted to the Registry. Thus, the input from physicians throughout the country is
evaluated and recorded . Hopefully,
for the first time, we have the
means to obtain realistic incidence
data about adverse drug effects.
The response from hospitals and
private physicians has been disappointing, in quantity and quality
but the program is young, and already the Journal of the American
Medical Association has carried
several brief pertinent articles describing recently discovered adverse
drug effects and summarizing drug
information derived from this new
facility.
The Federal Drug Administration has inaugurated a similar program that complements the AMA
Registry and expands the total data
gathering capability. FDA concern
in the matter is oriented somewhat
differently from that of the AMA.
Nevertheless, such activity in the
nation's highest medical councils
indicates the growing importance
of adverse drug effects.
The AMA Registry represented a
significant step toward meeting the
challenge of new responsibility that
accompanies increased capability.
Our remarkable therapeutic arsenal
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is a tribute to the commercial drug
industry and the devoted chemists
and pharmacologists of our medical
schools. But neither medical
schools, AMA, FDA, nor the industry
can solve the problem completely.
My plea has been, and is directed
to the physician on the firing line,
the doctor who prescribes the drug.
It is farthest from my intention to
suggest therapeutic timidity or homeopathy. Our predecessors in
medicine had limited diagnostic and
therapeutic resources. The complement of nostrums in their little
black bag was austere, but these
drugs were regarded as old familiar
friends. Some were worthless, others dangerous; some were impure
and unstandardized to the point of
unpredictability. The few effective
drugs were trusted allies whose
strengths and weaknesses were well
known. The practitioner of the past
attempted to compensate for lack
of material resources with meticulous attention to his patients, personal charm, kindness, and pervading equanimity.
His lonely hours of private hell,
tormented by his inability to come
to grips with most of the severe illnesses that he encountered, constitute a long, bleak chapter in
medical history . The modern physician is afforded rare glimpses of
this agony when faced with malignancy or degenerative disease or
neurologic illness. Modern pharmacology has brought this unhappy era to an end; we now enjoy
the privilege of fine, powerful,
well-standardi ze d therapeutic
weapons.
Now we must work to create an
atmosphere of rational caution and
critical evaluation, where each
physician will pause before putting
pen to prescription pad and ask
himself, "Do I know enough
about this drug to prescribe it?
Does the possible benefit I hope
to derive from this drug outweigh
its potential hazard?" I do not
preach therapeutic nihilism, but
rather therapeutic rationalism.
Thank you.
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